Jagsonpal Pharmaceuticals EBITDA vs. Shares Owned By Insiders
| JAGSNPHARM | 639.65 23.25 3.77% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 323.5 M | Current Value 174.5 M | Quarterly Volatility 112.9 M |
For Jagsonpal Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Jagsonpal Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Jagsonpal Pharmaceuticals Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Jagsonpal Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Jagsonpal Pharmaceuticals Limited over time as well as its relative position and ranking within its peers.
Jagsonpal |
Jagsonpal Pharmaceuticals Shares Owned By Insiders vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Jagsonpal Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Jagsonpal Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Jagsonpal Pharmaceuticals Limited is currently regarded as number one stock in ebitda category among its peers. It also is currently regarded as number one stock in shares owned by insiders category among its peers . The ratio of EBITDA to Shares Owned By Insiders for Jagsonpal Pharmaceuticals Limited is about 4,240,430 . As of now, Jagsonpal Pharmaceuticals' EBITDA is increasing as compared to previous years. Comparative valuation analysis is a catch-all model that can be used if you cannot value Jagsonpal Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jagsonpal Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Jagsonpal Shares Owned By Insiders vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Jagsonpal Pharmaceuticals |
| = | 323.46 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Jagsonpal Pharmaceuticals |
| = | 76.28 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Jagsonpal Shares Owned By Insiders Comparison
Jagsonpal Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Jagsonpal Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Jagsonpal Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Jagsonpal Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Jagsonpal Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Jagsonpal Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 588.7 M | 618.2 M | |
| Operating Income | 214 M | 111.4 M | |
| Income Before Tax | 298.7 M | 313.6 M | |
| Total Other Income Expense Net | 84.7 M | 88.9 M | |
| Net Income | 224.6 M | 116.5 M | |
| Income Tax Expense | 74.1 M | 77.8 M | |
| Net Income From Continuing Ops | 224.6 M | 235.9 M | |
| Net Income Applicable To Common Shares | 307.3 M | 322.7 M | |
| Interest Income | 3.7 M | 3.5 M | |
| Net Interest Income | -8.1 M | -7.7 M | |
| Change To Netincome | 102.2 M | 107.3 M |
Jagsonpal Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Jagsonpal Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Jagsonpal Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Jagsonpal Pharmaceuticals' important profitability drivers and their relationship over time.
Use Jagsonpal Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jagsonpal Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jagsonpal Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Jagsonpal Pharmaceuticals Pair Trading
Jagsonpal Pharmaceuticals Limited Pair Trading Analysis
The ability to find closely correlated positions to Jagsonpal Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jagsonpal Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jagsonpal Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jagsonpal Pharmaceuticals Limited to buy it.
The correlation of Jagsonpal Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jagsonpal Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jagsonpal Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jagsonpal Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Jagsonpal Pharmaceuticals position
In addition to having Jagsonpal Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Market Neutral Funds Thematic Idea Now
Market Neutral Funds
Funds or Etfs that invest in both long and short positions of different entities to enhance returns from broad market movements over time. The Market Neutral Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Market Neutral Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Jagsonpal Stock
To fully project Jagsonpal Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Jagsonpal Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Jagsonpal Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.